ASCO GU 2023 Conference Coverage
T

ASCO GU 2023 Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial: Evaluating Cabozantinib + Nivo & Ipi in 1L Advanced RCC of IMDC Intermediate or Poor Risk

By ASCO GU 2023 Conference Coverage FEATURING Thomas Powles
By ASCO GU 2023 Conference Coverage FEATURING Thomas Powles
211 views
March 1, 2023
Comments 1
Login to view comments. Click here to Login

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Featured Video

17:48
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh

Recommended

AUTOPLAY
RENALC-BLADDR-PROSCA 2024

RENALC 2024 - Hybrid Global Forum on GU Oncology

Tue, Nov 26, 2024
16:05

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views
17:50

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.8K views
29:25

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views
13:37

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

SIR 2023 Conference Coverage

N. Kothary

3.0K views
15:58

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

527 views
10:19

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

362 views
07:27

Opus One: Final Results - RFA in Axial Skeleton

Jason Levy

2.0K views
15:28

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

261 views
20:07

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

240 views
06:41

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

129 views
06:58

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very Favo…

2024 ASCO® Annual Meeting Insights Hub

M. Zarba

242 views
19:41

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

1.9K views
13:46

Overview of a SoC in 1L mRCC Focusing on the Long-Term Survival Data

David McDermott

245 views
16:14

ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC…

2024 ESMO Annual Meeting Insights Hub

C. Porta

174 views
22:03

RCC Highlights From ASCO® GU 2024

Dana-Farber Cancer Institute

W. Xu, T. Choueiri

331 views
06:33

ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation …

2024 ESMO Annual Meeting Insights Hub

C. Ciccarese

154 views
17:33

1L Treatment Approaches in aRCC: Current Data, Treatment Selection, …

Benjamin Garmezy

251 views
06:49

ASCO® 2024 Insights: "Belzutifan for Advanced Renal Cell Carcinoma"

2024 ASCO® Annual Meeting Insights Hub

E. Jonasch

196 views
19:00

New

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

108 views
06:55

ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC -…

2024 ESMO Annual Meeting Insights Hub

L. Albiges

112 views